Thermodynamic compatibility between cyclodextrin supramolecular complexes and surfactant

[Display omitted] Supramolecular structures based on cyclodextrins have been extensively used for drug delivery systems over decades. However, combining host and guest molecules in a pharmaceutical formulation is not a trivial process, being one of the majors concern the inclusion complex compatibil...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of pharmaceutics Vol. 544; no. 1; pp. 203 - 212
Main Authors:	Meira, Larissa H.R., Soares, Guilherme A.B., Bonomini, Homero I.M., Lopes, Juliana Fedoce, De Sousa, Frederico B.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 10-06-2018
Subjects:	Binding affinity Competition Host-guest interaction Supramolecular system Theoretical calculations Thermodynamic parameters Competition Thermodynamic parameters Host-guest interaction Binding affinity Theoretical calculations Supramolecular system
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	[Display omitted] Supramolecular structures based on cyclodextrins have been extensively used for drug delivery systems over decades. However, combining host and guest molecules in a pharmaceutical formulation is not a trivial process, being one of the majors concern the inclusion complex compatibility with other excipients presented in the final formulation. Herein, experimental and theoretical calculations were used to investigate the competition of sodium dodecyl sulfate (SDS) with atenolol (ATE) or losartan (LOS), antihypertensive drugs widely used in the treatment of hypertension. Our findings, using nuclear magnetic resonance and isothermal titrations calorimetry experiments and molecular dynamic simulations demonstrated that LOS remain included into CD cavity after excipient (SDS) addition, which was not verified for ATE ternary system, being the drug displaced by SDS molecule.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0378-5173 1873-3476
DOI:	10.1016/j.ijpharm.2018.04.036